Transient anti-CD40L co-stimulation blockade prevents immune responses against human bullous pemphigoid antigen 2: Implications for gene therapy

Journal of Investigative Dermatology

Volumn 129, Issue 5, 2009, Pages 1203-1207

  Lanschuetzer, Christoph M ^a,b   Olasz, Edit B ^a   Lazarova, Zelmira ^a   Yancey, Kim B ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BULLOUS PEMPHIGOID ANTIGEN 2; CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G; RAG2 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CONTROL GROUP; CONTROLLED STUDY; DRUG HALF LIFE; EPIDERMOLYSIS BULLOSA; GENE THERAPY; GRAFT FAILURE; GRAFT RECIPIENT; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN GRAFT; SPLEEN CELL; TRANSGENIC MOUSE; WILD TYPE;

EID: 65049084893     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2008.364     Document Type: Article

References (26)

1. Aoki-Ota M, Kinoshita M, Ota T, Tsunoda K, Iwasaki T, Tanaka S et al. (2006) Tolerance induction by the blockade of CD40/CD154 interaction in pemphigus vulgaris mouse model. J Invest Dermatol 126:105-13
2. Bauer JW, Lanschuetzer C (2003) Type XVII collagen gene mutations in junctional epidermolysis bullosa and prospects for gene therapy. Clin Exp Dermatol 28:53-60
3. Chen M, Woodley DT (2006) Fibroblasts as target, cells for DEB gene therapy. J Invest Dermatol 126:708-10
4. Darling TN, Bauer JW, Hintner H, Yancey KB (1997) Generalized atrophic benign epidermolysis bullosa. Adv Dermatol 13:87-119: discussion 120
5. Dellambra E, Pellegrini G, Guerra L, Ferrari G, Zambruno G, Mavilio F et al. (2000) Toward epidermal stem cell-mediated ex vivo gene therapy of junctional epidermolysis bullosa. Hum Gene Ther 11:2283-7
6. Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ (1993) Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 261:1328-30
7. Early GS, Zhao W, Burns CM (1996) Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol 157:3159-64
8. Ferrant JL, Benjamin CD, Cutler AH, Kalled SL, Hsu YM, Garber EA et al. (2004) The contribution of Fc effector mechanisms in the efficacy of antiCD154 immunotherapy depends on the nature of the immune challenge. Int Immunol 16:1583-94
9. Franzke CW, Bruckner P, Bruckner-Tuderman L (2005) Collagenous transmembrane proteins: recent insights into biology and pathology. J Biol Chem 280:4005-8
10. Gerritse K, Laman JD, Noelle RJ, Aruffo A, Ledbetter JA, Boersma WJ et al. (1996) CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 93:2499-504
11. Hintner H, Wolff K (1982) Generalized atrophic benign epidermolysis bullosa. Arch Dermatol 118:375-84
12. Honey K, Cobbold SP, Waldmann H (1999) CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression. J Immunol 163:4805-10
13. Jarvinen LZ, Blazar BR, Adeyi OA, Strom TB, Noelle RJ (2003) CD154 on the surface of CD4+CD25+ regulatory T cells contributes to skin transplant, tolerance. Transplantation 76:1375-3
14. Khavari PA (1998) Gene therapy for genetic skin disease. J Invest Dermatol 110:462-7
15. Mavilio F, Pellegrini G, Ferrari S, Di Nunzio F, Di lorio E, Recchia A et al. (2006) Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med 12: 1397-1402
16. Mohan C, Shi Y, Laman JD, Datta SK (1995) Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 154:1470-80
17. Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A (1992) A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci USA 89:65504
18. Ohyama M, Ota T, Aoki M, Tsunoda K, Harada R, Koyasu S et al. (2003) Suppression of the immune response against exogenous desmoglein 3 in desmoglein 3 knockout mice: an implication for gene therapy. J Invest. Dermatol 120:610-5
19. Olasz EB, Roh J, Yee CL, Arita K, Akiyama M, Shimizu H et al. (2007) Human bullous pemphigoid antigen 2 transgenic skin elicits specific IgG in wildtype mice. J Invest Dermatol 127:2807-17
20. Pearson T, Markees TG, Wicker LS, Serreze DV, Peterson LB, Mordes JP et al. (2003) NOD congenie mice genetically protected from autoimmune diabetes remain resistant, to transplantation tolerance induction. Diabetes 52:321-6
21. Qin S, Cobbold SP, Pope H, Elliott J, Kioussis D, Davies J et al. (1993) "Infectious" transplantation tolerance. Science 259:974-7
22. Rosenberg AS, Singer A (1988) Evidence that the effector mechanism of skin allograft rejection is antigen-specific. Proc Natl Acad Sci USA 85:773942
23. Roy M, Waldschmidt T, Aruffo A, Ledbetter JA, Noelle RJ (1993) The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. J Immunol 151:2497-510
24. Van den Bergh F, Giudice GJ (2003) BP180 (type XVII collagen) and its role in cutaneous biology and disease. Adv Dermatol 19:37-71
25. van Kooten C, Banchereau J (2000) CD40-CD40 ligand. J Leukoc Biol 67:2-17
26. Woodley DT, Remington J, Huang Y, Hou Y, Li W, Keene DR et al. (2007) Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen, and promote wound healing. Mol Ther 15:628-35